An in -
crease in major bleeding was present with enoxaparin
(RR 1.53, 95% CI 1.23–1.89).33 Head-tohead
comparison of enoxaparin and fondaparinux
was done in non–ST elevation acute coronary syndrome
and showed that fondaparinux caused fewermajor bleeding events (HR 0.52, 95% CI 0.44–
0.61) without compromising efficacy..